Modified Mediterranean diet vs. Traditional Iranian diet:Efficacy of dietary interventions on dietary inflammatory index score, fatigue severity and disability in multiple sclerosis patients by Bohlouli, Jalal et al.




Modified Mediterranean diet vs. 
Traditional Iranian diet: Efficacy of 
dietary interventions on dietary 
inflammatory index score, fatigue 
severity and disability in multiple 
sclerosis patients 
 
Jalal Bohlouli, Iman Namjoo, Mohammad Borzoo-Isfahani, Fariborz 
Poorbaferani, Amir Reza Moravejolahkami, Cain CT Clark, and Mohammad 
Ali Hojjati Kermani 
 
Author post-print (accepted) deposited by Coventry University’s Repository 
 
Original citation & hyperlink:  
Bohlouli, J., Namjoo, I., Borzoo-Isfahani, M., Poorbaferani, F., Moravejolahkami, A.R., Clark, 
C.C. and Kermani, M.A.H., 2021. Modified Mediterranean Diet VS. Traditional Iranian Diet: 
Efficacy of Dietary Interventions on Dietary Inflammatory Index Score, Fatigue Severity and 
Disability in Multiple Sclerosis Patients. British Journal of Nutrition 
https://dx.doi.org/10.1017/S000711452100307X   
 
DOI:  10.1017/S000711452100307X 
ISSN:     0007-1145 
e-ISSN: 1475-2662 
 
Publisher: Cambridge University Press 
 
This article has been published in a revised form in British Journal of Nutrition 
[http://doi.org/ 10.1017/S000711452100307X]. This version is published under a 
Creative Commons CC-BY-NC-ND. No commercial re-distribution or re-use 





This peer-reviewed article has been accepted for publication but not yet copyedited or typeset, 
and so may be subject to change during the production process. The article is considered 
published and may be cited using its DOI 
10.1017/S000711452100307X 
The British Journal of Nutrition is published by Cambridge University Press on behalf of The 
Nutrition Society 
Original article 
Modified Mediterranean Diet VS. Traditional Iranian Diet: Efficacy of Dietary 
Interventions on Dietary Inflammatory Index Score, Fatigue Severity and Disability in 




, Iman Namjoo 
2
, Mohammad Borzoo-Isfahani 
3














Department of Nutrition, Nutrition and Food Security Research Centre, School of Public Health, 
Shahid Sadoughi University of Medical Sciences, Yazd, Iran. Email: Bohlooljalal@gmail.com. 
ORCID ID: 0000-0003-0266-2537. 
2
Department of Community Nutrition, School of Nutrition & Food Science, Isfahan University 
of Medical Sciences, Isfahan, Iran. Email: inamjoo91@gmail.com; i.namjoo@nutr.mui.ac.ir. 
ORCID ID: 0000-0002-1889-2866. 
3 
Department of Community Nutrition, School of Nutrition & Food Science, Isfahan University 
of Medical Sciences, Isfahan, Iran. Email: nutr.borzoo@gmail.com . ORCID ID: 0000-0003-
2020-9920.  
4
Food Security Research Center, Department of clinical Nutrition, School of Nutrition & Food 
Science, Isfahan University of Medical Sciences, Isfahan, Iran. Email: 




Department of Clinical Nutrition, School of Nutrition & Food Science, Isfahan University of 
Medical Sciences, Isfahan, Iran. Emails: a.moravej@mail.mui.ac.ir; amimohs@gmail.com. 
ORCID ID: 0000-0001-9707-0352. 
6
Centre for Intelligent Healthcare, Coventry University, Coventry, CV1 5FB, U.K. Email: 
ad0183@coventry.ac.uk.  ORCID ID: 0000-0002-6610-4617. 
7
Clinical Tuberculosis and Epidemiology Research Center, National Research Institute of 
Tuberculosis and Lung Diseases (NRITLD), Shahid Beheshti University of Medical Sciences, 
Tehran, Iran. Email: Imhojjati@gmail.com. ORCID ID: 0000-0002-2364-3696. 
*Corresponding author: Dr. Amir Reza Moravejolahkami, Department of Clinical Nutrition, 
School of Nutrition and Food Sciences, Isfahan University of Medical Sciences, Hezar-Jerib 
Ave, Isfahan, IR Iran. P.O. Box 81746-73461. Tel: +98(31)33354453, Cell phone: 
+989136448771, Fax: +98(31)36681378, E-mails: a.moravej@mail.mui.ac.ir, 
amimohs@gmail.com, ORCID ID: 0000-0001-9707-0352. 
Running head: Mediterranean diet and multiple sclerosis 
This study has not been duplicate publication or submission elsewhere. The authors received no 
financial support for the research and/or authorship of this article. The authors declare that they 
have no conflict of interest to the publication of this article.  
CRediT author statement 
Jalal Bohlouli: Investigation, Funding acquisition 
Iman Namjoo: Visualization, Project administration 
Mohammad Borzoo-Isfahani: Data Curation, Resources 
Fariborz Poorbaferani: Formal analysis 
Amir Reza Moravejolahkami: Conceptualization, Methodology, Software, Validation, Formal 
analysis, Writing - Review & Editing, Supervision 
Cain C. T. Clark: Writing - Review & Editing 






The authors thank all the participants of the study for their enthusiastic of involvement and to the 
personnel of the clinic. This research was supported by Student Research Committee of Isfahan 
University of Medical Sciences, Isfahan, Iran (Grant NO. 197140).  
Trial Registration: The trial was registered at the University of Medical Science 
“IR.MUI.RESEARCH.REC.1397.287” and WHO approving system 
“IRCT20181113041641N1”. 
The protocol is also visible at CCHRANE LIBRARY 
(https://www.cochranelibrary.com/central/doi/10.1002/central/CN-01949901/full)  







Current evidence suggests that adherence to the Mediterranean Diet (MeD) can reduce 
inflammation in chronic diseases; however, studies pertaining to Relapsing-Remitting Multiple 
Sclerosis (RRMS) are limited. Therefore, the aim of this study was to investigate the potential of 
the modified MeD (mMeD) in improving Dietary Inflammatory Index (DII) scores, disability, 
and fatigue severity, compared to Traditional Iranian Diet (TID), in RRMS patients. 
Methods  
After initial screening (n=261), 180 RRMS patients were randomized to receive mMeD or 
TID (as control) for six months. DII score, Expanded Disability Status Scale (EDSS) and 21-item 
Modified Fatigue Impact Scale (MFIS) were evaluated at baseline and trial cessation. 
Multivariate analysis of covariance was conducted and adjusted for age, gender, body weight, 
body mass index, education level, supplement use, family history and duration of MS. 
Results  
Of the 180 patients enrolled, 147 participants were included in the final analysis (n of 
mMeD=68; n of TID=79). Self-reported adherence was good (~81%). Dietary intakes of 45 food 
parameters were assessed through the food frequency questionnaire. The mMeD significantly 
reduced DII scores after six months (2.38±0.21 to -1.87±0.86, P<0.001), but TID did not elicit 
any changes (2.21±0.44 to 2.14±1.01, P=0.771). Additionally, MFIS total score decreased 
significantly (72.4±17.2 to 63.9±14.2, P<0.001), whereas there was no considerable 
improvement for EDSS in the mMeD group. 
Conclusion  
Adherence to mMeD, for six months, improved dietary inflammatory status and fatigue 
severity in RRMS patients, however, the traditional Iranian diet did not positively impact dietary 
inflammation and MFIS score.  
Keywords: Dietary inflammatory index; Mediterranean diet; fatigue; multiple sclerosis; 





Multiple Sclerosis (MS) is an autoimmune disease of the central nervous system, with 
unknown etiology, characterized by chronic inflammation, demyelination, and neuronal loss [1]. 
Around 2.5 million individuals, worldwide, are affected by this disease [2], although young 
adults and females are more susceptible [3]. Relapsing-Remitting MS (RRMS), the most 
common type of MS, is indicated in, roughly, 85% of patients [4]. 
Contentions in the literature regarding the relationship between some dietary components and 
MS progression are evident. For example, dietary polyphenols have been reported to mitigate 
demyelination [5], whereas, resveratrol - a polyphenol compound found in a variety of foods and 
beverages - reportedly exacerbated both autoimmune and viral models of MS [6]. Milk proteins 
and gluten may worsen the clinical manifestations in MS patients [7], however, milk 
consumption more than once per week was found to decrease the risk of developing MS [8]. 
Furthermore, high doses of vitamin C have been shown to worsen MS conditions [9], while some 
authors have reported that vitamin C promotes oligodendrocytes generation and remyelination 
[10]. Indeed, more nutrition-based research is required to clarify these conflicting findings. 
Among the most advocated healthy diets, the Mediterranean Diet (MeD) has the strongest 
evidence for improvement in inflammatory status [11]. This diet is characterized by high intake 
of vegetables, legumes, fruits, whole grains, and unsaturated fatty acids (mostly in the form of 
olive oil), a moderately high intake of fish, and low to moderate intake of dairy products, meat, 
and poultry [12]. Indeed, previous studies have shown the potential effects of anti-inflammatory 
diets, such as Mediterranean-style diets, in reducing fatigue severity in MS patients [12-14].  
Dietary Inflammatory Index (DII), a literature-based scoring system, is a tool used to classify 
forty-five pro or anti-inflammatory dietary items into an overall score [15]. Previous studies have 
reported that several foods and nutrients used in the DII calculation, such as whole grains, fruits, 
vegetables, fish, onion, and ginger possess anti-inflammatory effects [16, 17]. In contrast, refined 
grains, red meat, high-fat dairy products, and sweats have been routinely related to systemic 
inflammation [18]. In previous studies, MeD reportedly yielded a strong anti-inflammatory DII 
score [19] and greater MeD adherence has been negatively associated with DII scores [20, 21]. 
On the other hand, some findings suggest that higher DII scores during adolescence might be an 
important risk factor for MS onset [22]. 
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Therefore, given the equivocality present within the literature, we sought to determine the 
effect of mMeD vs. TID, on DII, disease disability, and fatigue severity in RRMS patients. We 
hypothesized that the modified form of MeD (mMeD; mainly by elimination of alcohol-
containing foods and beverages) would yield a lower DII score (i.e., greater dietary anti-
inflammatory potential) in comparison with the Traditional Iranian Diet (TID). 
  
2. Materials & Methods  
2.1. Study design and sample size determination 
In this single-center, two parallel arms, single-blind, randomized clinical trial, 180 RRMS 
patients were recruited, according to the Extended Disability Status Scale (EDSS 0-3, mild to 
moderate disability as diagnostic criteria) [23]. Intervention delivery was performed from July 
2018 to February 2019.  
The study protocol was approved by ethics committee located in the University Medical 
Sciences, and WHO-related Registry of Clinical Trials (IRCT20181113041641N1). The Helsinki 
ethical principles [24] were well observed throughout the trial. Study objectives were explained, 
and voluntary informed consent was taken prior to data collection.  
Fatigue Severity Scale (FSS), a tool for measuring fatigue in MS, was used to calculate the 
sample size based on previous reports [25].  
   
        
    
     
  
           
   
      
 
        
By the use of sample size determination formula (S1, SEM for FSS in control group=4.73; S2, 
SEM for FSS in intervention group=4.85;         , mean changes for FSS=3), with a confidence 
level of 95% (z1=1.96), power of 80% (z2=1.64), and drop-out rate of 35 % in the number of 
participants, the total sample size was estimated to be 180. 
 
2.2. Inclusion and exclusion criteria 
Eligible patients had mild to moderate RRMS (defined as EDSS up to 3, and who received 
dimethyl fumarate 240 mg twice daily in the last year), aged between 20-60 years old, and ability 
to write or recall dietary history. Subjects were excluded if they had any of the following: other 
forms of MS and disease duration of less than one year with active relapses, viral infections such 
as Epstein Barr, major medical illnesses (such as cancer, allergy, other autoimmune diseases, 
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anticoagulant or antiplatelet use, and psychiatric disorders), and current smokers (one or more 
cigarette per day). Subjects were also excluded if they left more than 40% blank items on the 
Food Frequency Questionnaire (FFQ) at baseline or were prescribed high dose corticosteroid 
therapy (greater than 30 mg/day methylprednisolone). 
 
2.3. Interventions and control groups 
The main composition of each diet has been described briefly in Table 1. The intervention 
group followed a modified version of MeD (mMeD; 17 % protein, 51 % carbohydrate and 32 % 
fat [26]), based on higher intake of fresh fruits and vegetables, whole grains, monounsaturated 
fatty acids, fish, and low to moderate consumption of dairy products, meat, and poultry. In 
practice, the prescribed mMeD was individualized based on cultural and personal preferences, 
and the elimination of any alcohol-containing foods and beverages. The control group followed 
the TID (low in low-fat dairy products, whole grains; high in red meats, solid oils, refined 
grains, and moderate intakes of legumes, fruits and vegetables); based on prior investigations, 
this diet consisted of 13 % protein, 58 % carbohydrate and 29 % fat [27]. It must be noted that 
the TID group (as control) did not continue their normal eating pattern, i.e., the original dietary 
principles in the control group were maintained, however, the TID plan was adjusted for energy 
intake to avoid unexpected body weight changes.  
Ideal body weight and the Harris-Benedict equation [28] were utilized to calculate the Basal 
Energy Expenditure (BEE) for each participant in both diets (mMeD and TID). Next, the above 
percentages were used to discern the macronutrient requirements in both diets. All the 
participants received an individualized diet plan, which had been designed according to the 
above principles. Dietary adherence was also measured with weekly with phone calls, and face-
to-face interviewing every month.  
 
2.4. Recruitment and randomization methods 
Participants were recruited using advertisements in local media outlets and clinicians’ 
invitation. Participants were randomly assigned into either the modified Mediterranean Diet 
(mMeD; intervention) or Traditional Iranian Diet (TID; control) group, with a computerized 
random sequence generator. Randomization was performed by a research assistant who did not 




In this trial, blinding of participants and dietitians is not possible because of obvious 
differences between the intervention and control diets; however, where appropriate, trial 
personnel (research assistant who enrolled participants, outcome assessors and data analysts) 
remained blind to group allocation throughout the study period. 
2.6. Outcome measurements 
The primary outcome was the diet-induced change in DII. The secondary outcomes were 
change in disease disability (measured by EDSS) and fatigue severity (measured by MFIS). 
Sociodemographic and clinical characteristics were collected through a self-report survey 
completed at baseline, which included details on participants’ age, body weight and height, Body 
Mass Index (BMI), education level, family history of MS, and supplement use. Baseline DII 
scores were also assessed in two states: dietary only and dietary plus supplements. However, the 
statistical analysis was conducted based on dietary DII scores. 
 
2.6.1. Dietary assessment 
Food intake of individuals during the previous year was assessed using a validated 168-item 
semi-quantitative FFQ [29], which included a list of foods with standard serving sizes commonly 
consumed [30-32]. Nutritionist IV software (N-squared Computing, Salam, OR, USA) was used 
to analyze the composition of consumed foods. Some DII parameters such as ginger, saffron, 
turmeric, thyme/oregano, and rosemary were additionally added to the FFQ. For calculation of 
flavonoids (flavan-3-ol, flavones, flavonols, flavonones, anthocyanidins and isoflavones), the 
USDA Databases for the Flavonoid Content of Selected Foods (Release 3.3, March 2018) [33] 
and Isoflavone Content of Selected Foods (Release 2.0, September 2008) [34] were used. Dietary 
intake of eugenol was estimated according to Phenol-Explorer database (latest version 3.6; 
released on December 2016) [35]. There were two timepoints for dietary assessment: one before 
the dietary intervention and one 6 months after the start of the study.  
 
2.6.2. DII calculation  
Shivappa et al. [36], after evaluation of 1943 articles (were published between 1950 and 
2010), examined the association between inflammation and 45 food and nutrient parameters; this 
resulted in the development and validation of DII, where the score ranged from 7.98 (i.e., 
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strongly pro-inflammatory) to -8.87 (i.e. strongly anti-inflammatory). In the present study, we 
calculated the DII scores at baseline and after 6 months of intervention. Estimated dietary intake 
data were adjusted against a reference global daily mean and standard deviation intake (from 11 
countries) [36] for each parameter to obtain a Z-score; each Z-score was converted to percentile, 
and this value was multiplied by 2 and then subtracted from 1. This number for each intake 
parameter was multiplied by its respective parameter-specific inflammatory effect score to obtain 
the parameter-specific DII score. Each of these 45 scores were then summed to obtain an overall 
DII score. 
 
2.6.3. Fatigue Severity Assessment 
The Modified Fatigue Impact Scale (MFIS) was used to determine the MS-related fatigue 
[37] at baseline and 6 months after the intervention. This standard 21-item questionnaire has 
three subscales (Physical, ranges from 0-36; Cognitive, 0-40; and Psychosocial, 0-8). The total 
score is computed by summing scores from the three subscales and ranges from 0-84, where 
higher scores represent greater fatigue severity. In the present study, the validated Persian 
version of MFIS [38], with excellent test-retest reliability [39], was utilized. 
 
2.6.4. Disability Assessment 
A trained neurologist measured EDSS to assess MS-related disability [23, 40] at baseline and 
6 months after the intervention. Scales for the total EDSS in the current study ranged from 0 (no 
disability at all) to 3 (mild to moderate disability).  
 
2.7. Statistical analysis 
Data were presented as means ± Standard Deviation (SD) for continuous variables and 
number (percent) for categorical variables. The Kolmogorov–Smirnov test was used to assess the 
normality of continuous variables. In addition, independent student t and paired t tests (or non-
parametric Mann–Whitney U and Wilcoxon tests) were used to compare the continuous 
variables. Categorical variables were compared using the χ2 or Fisher's Exact test. Multivariate 
Analysis of Covariance (MANCOVA) was performed to evaluate the differences for change in 
DII scores, where the related values were adjusted for age, gender, body weight, BMI, education 
level, supplement use, family history, and duration of MS. The mean changes (∆) were 
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calculated by subtracting the baseline and 6 months (end) values. To identify the relationship 
between DII (and other covariates) and fatigue severity/ disease activity scores at end of trial, 
multiple regression analysis was performed. All statistical analyses were conducted using 
Statistical Package for the Social Sciences (SPSS), version 24 (SPSS Inc.). P<0.05 was 
considered to represent statistical significance. 
 
3. Results 
3.1. Enrollment and adherence 
Between July 2018 and February 2019, we screened 261 RRMS patients, however, sixty-
seven subjects were excluded as they did not meet the inclusion criteria, and fourteen patients 
declined to participate (Figure 1). 180 patients were dichotomized to the mMeD or TID group. 
Thirty subjects dropped out during the study follow-up: twenty due to lack of compliance, two 
due to lack of willingness to continue the study, one due to a driving accident, and ten subjects 
due to incomplete questionnaires. Overall, 147 participant-related data (intervention=68; 
control=79) were analyzed (based on per-protocol analysis). No side effects (diarrhea, abdomen 
pain, constipation, and appetite changes) were reported during the study period. 
 
3.2. Baseline characteristics 
Sociodemographic and medical characteristics, between the groups at baseline, are reported 
in Table 2. Overall, the participants were middle-aged adults (with mean age 39.3 ± 9.2 years 
old; ~83% female). More than 40 % were overweight and obese, 15 % had family history of MS, 
and the majority had already completed a degree to diploma level. More than 80 % of the study 
population were taking at least one type of nutritional supplement, of which vitamin D (~83 %) 
and omega-3 (~33%) were the most common. Additionally, ~20 % of subjects had consumed L-
carnitine or caffeine-containing supplements during the past six months. A small number of male 
participants (13 %) were irregular smokers (average 1-2 cigarettes in a week). Mean EDSS score 
was slightly higher in the control group (2.0 vs. 1.7), although there were no significant 





3.3. Clinical outcomes 
3.3.1. Impact of diet interventions on DII 
Table 3 details the mean daily intake for 45 DII parameters and overall DII score for each 
diet. Within the mMeD group, there was a significant decrease from 2.38 ± 0.21 to -1.87 ± 0.86 
at 6 months for overall DII score (P< 0.001). Compared with control group (TID), the mean 
changes for overall DII score were also statistically significant (-4.25 ± 1.54 vs. -0.07 ± 0.62; P< 
0.001). 
For mean daily intake of DII food/nutrient parameters after 6 months (Table 3), there was a 
significantly higher intake of protein, n-6 Fatty acids, Monounsaturated Fatty Acids (MUFA), 
Polyunsaturated Fatty Acids (PUFA), selenium, beta carotene, vitamin E, riboflavin, garlic, 
onion, ginger, turmeric, pepper, thyme/oregano, rosemary, flavan-3-ol, anthocyanidins, 
isoflavones; in addition to lower intake of energy, carbohydrate, total fat, saturated fat, trans fat, 
iron, and caffeine in the mMeD group compared to TID group (P< 0.05). 
 
3.3.2. Impact of diet interventions on fatigue 
Table 4 details the results for fatigue severity. At the end of the study period, MANCOVA 
revealed a significant difference between the groups for MFIS total score (∆ for mMeD= -8.5 ± 
2.74 vs. ∆ for TID= 6.4 ± 1.62, P< 0.001). These findings were adjusted for age, gender, body 
weight, BMI, education level, supplement use, family history, and duration of MS. 
Participants who received mMeD had a statistically significant improvement in physical and 
cognitive MFIS subscales. After six months, there was a 2.7 and 5.6 points reduction in physical 
(P< 0.001) and cognitive (P= 0.027) MFIS subscales, respectively. However, no significant 
change in the psychosocial subscale of MFIS was evident. 
 
3.3.3. Impact of diet interventions on disability 
There was a non-significant reduction in EDSS at the end of the study period in the mMeD 
group (∆= -0.02 ± 0.07, P= 0.334). Contrastingly, a non-significant rising trend in EDSS was 
seen in the TID group. MANCOVA, adjusted for age, gender, body weight, BMI, education 
level, supplement use, family history, and duration of MS, did not indicate any significant 




3.3.4. Relationship between DII and the fatigue severity/disease disability  
Significant predictors and covariates for MFIS total score and EDSS are presented in Table 5. 
DII score significantly predicted fatigue severity in the intervention group (B= 1.701, P= 0.041; 
adjusted R
2
= 0.098), however, age, gender, body weight, BMI, education level, supplement use, 
family history, and duration of MS had no significant association with MFIS total score. 
In addition, regression analysis revealed that DII score does not predict disease disability in 
mMeD group (B= 3.809, P= 0.067; adjusted R
2
= 0.157). Other covariates (age, gender, body 
weight, BMI, education level, supplement use, family history, and duration of MS) did not show 
any significant association with EDSS.  
 
4. Discussion 
This study assessed the effects of dietary intervention on DII score in Iranian RRMS patients. 
Our findings showed that the mMeD possesses significant anti-inflammatory properties, whereas 
the Traditional Iranian Diet (TID) had no significant effect on overall DII score. The key 
components of DII i.e., MUFA and polyphenols, increased significantly after six months 
adherence to the mMeD group. Moreover, mMeD also reduced fatigue severity (MFIS score); 
however, the effect on disease disability (measured by EDSS) was not significant. 
Iranian dietary intervention studies typically use TID as the control diet [11, 41, 42]. TID 
(low in low-fat dairy products, whole grains; high in red meats, solid oils, refined grains, and 
moderate legumes, fruits and vegetables) is the most prevalent diet in Iran, and has both positive 
and negative health-related aspects [43]. In a case-control study, conducted by Jahromi et al. 
[44], the traditional dietary pattern was inversely related to the risk of RRMS; however, high 
amounts of red/organ meat in the TID can lead to both neurodegeneration and autoimmune 
disorders [45]. Indeed, it must be noted that nutritional transition in Iran has resulted in a change 
in TID, which must be considered in further research [43, 46]; however, the control group 
adhered to the prescribed TID, as defined in the present study.  
In this research, DII was considered as an index that effectively represents dietary 
inflammatory status, based on several previous studies that have verified by the significant 
association of DII with inflammatory markers [47]. This index presents an alternative assessment 
tool for inflammation, as opposed to the laboratory-based techniques which are obtained through 
invasive methods and economically prohibitive [48]. Moreover, some previous studies have 
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indicated that the DII may also be correlated with other dietary indices i.e., Healthy Eating 
Index-2010 (HEI-2010), the Alternative Healthy Eating Index (AHEI), and the Dietary 
Approaches to Stop Hypertension Index (DASH) [49].  
Regardless of the pro-inflammatory DII score for the TID, the mMeD elicited a reduction in 
the total DII score in the present study. Indeed, the association between MeD and DII score has 
been evaluated in previous research; for instance, in a Spanish cross-sectional study, adherence 
to the MeD was higher in the lowest quintile of DII scores [20]. Moreover, an inverse correlation 
was also observed between the DII and Mediterranean Diet Score [21], whilst Mayr et al. [19] 
showed that  six months MeD adherence, compared with a low-fat diet, elicited an improvement 
in DII scores in patients with coronary heart disease. Interestingly, Mayr et al. evaluated 45 
parameters of DII and reported an anti-inflammatory DII score of -1.74, which is comparable to 
the total score of -1.87 in the present study. Although we removed the alcohol-containing foods 
and beverages from our intervention, the current findings were comparable to the intact versions 
of the MeD reported in the literature. 
Recently, it was reported that DII was not significantly associated with the clinical condition 
of individuals with MS [50]. Moreover, Silva et al. [51], in a cross-sectional study, reported that 
DII does not correlate to waist circumference, waist-hip ratio, body roundness index, body shape 
index, body shape z score index, and percentage of body fat among MS patients. In contrast, 
Shivappa et al. [52] observed that a pro-inflammatory diet (with a higher DII score) may be 
associated with an increased risk of MS in an Iranian population. In the current study, an anti-
inflammatory diet was prescribed to assess the possible effects on DII in RRMS patients. The 
link between diet and chronic inflammation has been well established [53, 54], and the 
association between inflammation and neurodegeneration in MS is generally well-supported 
[55]. According to previous work, the Mediterranean diet is inversely associated with biomarkers 
of inflammation [56, 57].  
The MUFA and PUFA content of mMeD appears to be responsible for the anti-inflammatory 
DII score in the current study. Omega-3 PUFAs inhibit NF-kB signaling through activation of 
SIRT1-mediated pathway [58] and the reduction of pro-inflammatory cytokines (e.g., IL-12, IL-
23) [59]. Olive oil polyphenols, which are a major part of the mMeD, also have an inhibitory 
effect on endothelial Nitric Oxide Synthase (eNOS) and Brain-Derived Neurotrophic Factor 
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(BDNF) expression [60]. However, two systematic reviews in 2012 and 2020, respectively, 
reported that PUFAs do not elicit any significant effect on MS-related outcomes [61, 62]. 
In the present study, flavonoids intake increased after six months adherence to the mMeD; 
moreover, flavan-3-ol, anthocyanidins, and isoflavones levels were significantly greater in 
comparison with the TID group. Flavan-3-ols, mainly extracted from green tea, have previously 
been advocated as neuroprotective compounds [63]. Furthermore, anthocyanidins possess anti-
inflammatory and anti-proliferative effects through inhibition of the cyclooxygenase-2 
expression in LPS-evoked macrophages [64]. Recently, Freedman et al. [65] found that a high-
isoflavone diet ameliorates Experimental Autoimmune Encephalomyelitis (EAE) through 
modulation of gut microbiota in MS patients. 
In the present study, fatigue severity was reduced by 12 percent (measured by MFIS total 
score). In a 12-week randomized trial, Mousavi-Shirazi-Fard et al. [13] observed the fatigue-
modulatory effect of an anti-inflammatory diet among 100 RRMS patients. Another study, 
conducted by Yadav et al. [66], reported that a plant-based, low-fat diet, can reduce the MFIS by 
~0.2 points per month in RRMS patients. Indeed, it seems that the bioactive components of 
mMeD are responsible for fatigue improvement. 
The mMeD administration in the present study did not elicit any improvement in disease-
related disability in RRMS participants. We hypothesized that the mMeD may have improved 
the level of disability from moderate (~3) to mild disability (≤2); however, in this study, and our 
previous work, there was no association between a Mediterranean-like dietary pattern and 
disability (measured by EDSS) [14]. EDSS is the most important secondary endpoint in MS 
trials addressing RRMS patients; this instrument is suitable for detecting the efficacy of clinical 
interventions, to monitor disease progression, and is internationally utilized [67]. 
While our study provides initial insights into understanding the potential role of dietary 
interventions in the management of MS, it has some limitations that should be considered. The 
current study is representative of patients with RRMS undergoing intensive pharmacotherapy, 
and who are potentially motivated and health-conscious. Therefore, the current findings are not 
necessarily pertinent to healthy subjects, or other disease populations. The sample size for the 
present study was calculated based on a secondary variable, i.e., FSS. Furthermore, incumbent 
findings could have been affected by insufficient statistical power, relative to DII score, small 
sample size, short follow-up period, and high drop-out rate (>18%). Moreover, there was an 
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imbalance between groups at follow-up in the drop-out rate (more than 22% in the intervention 
group versus 3.3 % in the control group). The nature of this study was single-blind and was 
vulnerable to selection and recall biases. The lack of neuroimaging data, which may be useful in 
evaluating the effect of diet on neurodegeneration, was the most important clinical limitation. 
The calculation of trans fat intake was predominantly based on high-fat dairy and meat products; 
thus, underestimation was possible. Finally, EDSS was used to measure disease disability in the 
current research; however, this tool may not be sensitive to clinical change, especially in short-
term studies (≤ 6 months) and milder levels of disability [68].  
However, despite the aforementioned limitations, the present study has several strengths 
worth mentioning. The MS participants recruited were relatively homogenous, allowing pertinent 
inferences to be drawn. Furthermore, adjustment in the final analysis allowed detailed 
consideration of potential confounding variables. In this trial, all 45 parameters of the DII were 
measured and a non-invasive method was used for evaluating inflammatory condition; these 
strategies helped to improve the accuracy and precision of our findings. Finally, although current 
evidence suggests that adherence to a Mediterranean-style diet can reduce inflammation in 
chronic diseases, studies pertaining to Relapsing-Remitting Multiple Sclerosis (RRMS) are 
limited; therefore, the present study provides a novel and important addition to the literature. 
 
5. Conclusion 
Our results demonstrated that adherence to the mMeD for 6-months can reduce DII score in 
RRMS participants. Indeed, the mMeD improved fatigue severity, without any significant 
change on disability. Comparatively, adherence to the Traditional Iranian Diet did not impact DII 
scores. Additional studies are required to evaluate the long-term safety and immunomodulatory 
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Table 1. The main composition of modified Mediterranean (mMeD) and Traditional Iranian 
(control) diets. 
Major nutrients mMeD Control† 
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‡modified Mediterranean Diet; adopted from 1999 Greek Dietary Guidelines (1999): 
Ministry of health and welfare, supreme scientific health council: Dietary guidelines for 
adults in Greece.Arch. Hell. Med. 1999, 16, 516–524. Serving sizes specified as: 25 g 
bread, 100 g potato, 50–60 g cooked pasta, 100 g vegetables, 80 g apple, 60 g banana, 
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Table 2. Characteristics of participants between diet study groups. 
group 
 
continuous  variables 
mMeD 
(n=68) 
M ± SD 
Control 
(n=79) 




Age (y) 38.6 ± 8.6 40.0 ± 9.6 0.309 
Body Weight (kg) 71.2 ± 10.1 68.5 ± 10.5 0.556 
Height (cm) 165.4 ± 7.0 163.0 ± 6.8 0.473 
BMI (kg/m
2
) 26.1 ± 4.1 25.9 ± 4.5 0.757 
Duration of the disease (y) 8.1 ± 5.7 9.3 ± 6.9 0.395 
EDSS 1.7 ± 0.7 2.0 ± 0.9 0.059 
DII
‡
 2.38 ± 0.21 2.38 ± 0.21 0.687 












Male (17%) 11 (16.2) 14 (17.7) 
0.830 
Female (83%) 57 (83.8) 65 (82.3) 
Education 
Illiterate 3 (4.4) 3 (3.8) 
0.332 
Elementary 7 (10.3) 5 (6.3) 
Junior school 7 (10.3) 9 (11.4) 
Diploma 29 (42.6) 46 (58.2) 
University 22 (32.4) 16 (20.3) 
Family 
history 
Yes 10 (14.7) 12 (15.2) 
0.999 




Normal 28 (41.2) 34 (43.0) 
0.948 
Underweight 2 (2.9) 3 (3.8) 
Overweight 18 (26.5) 22 (27.8) 
Obese 20 (29.4) 20 (25.3) 
Nutritional 
supplement 
Vitamin D 60 (88.2) 62 (78.5) 
0.764 
Omega-3 26 (38.2) 23 (29.1) 
 
intakes Multivitamin & 
minerals 
18 (26.5) 17 (21.5) 
L-carnitine or 
caffeine 
11 (16.1) 18 (22.8) 
Abbreviations: mMeD, modified Mediterranean Diet; BMI, Body Mass 
Index; yr, year; SD, Standard Deviation; EDSS, Extended Disability 
Status Scale; %, within group percent; DII, dietary inflammatory index; 
control, Traditional Iranian Diet. 
†
obtained from independent t-test, EXCEPT for Duration of the disease, 
BMI, and EDSS, that was analyzed by Man-Whitney U test; P<0.05 
considered significant 
‡
determined with Chi Square, EXCEPT for gender, and Family history, 
that was analyzed by Fisher’s Exact test,  P<0.05 considered significant 
§
Negative number represents an anti-inflammatory score, while positive 





Table 3. Dietary inflammatory index (DII) parameters and scores in patients with relapsing-remitting m clerosis that received 
either modified Mediterranean Diet (mMeD) or Traditional Iranian Diet (control). 
Dietary group DII food 
parameters 
Group Baseline End of trial P-val 2 P-value
3 
energy Energy (kcal/day) 
mMeD 2670.6 ± 468.6 2193.6 ± 317.3 <0.00 -477.0 ± 300.1 
<0.001* 
Control 2575.7 ± 437.0 2588.7 ± 419.5 0.828 13.0 ± 531.5 
Macro nutrients 
Carbohydrate (g/day) 
mMeD 405.2 ± 86.6 317.5 ± 57.7 <0.00 -87.7 ± 54.2 
<0.001* 
Control 391.4 ± 78.3 394.8 ± 75.1 0.083 3.4 ± 97.3 
Protein (g/day) 
mMeD 92.0 ± 7.5 87.0 ± 8.4 <0.00 -5.0 ± 8.8 
0.327 
Control 90.5 ± 6.9 90.1 ± 7.1 0.642 -0.36 ± 10.0 
Total fat (g/day) 
mMeD 77.3 ± 13.1 66.9 ± 7.5 0.001 -10.4 ± 12.4 
0.052 
Control 74.0 ± 13.0 74.0 ± 12.7 0.057 0.10 ± 15.8 
Cholesterol (mg/day) 
mMeD 307.1 ± 105.3 266.0 ± 37.2 0.055 -81.1 ± 103.2 
0.134 
Control 283.8 ± 104.6 284.8 ± 105.2 0.072 1.0 ± 132.4 
Saturated fat (g/day) 
mMeD 26.5 ± 10.4 18.7 ± 5.2 0.002 -7.8 ± 9.7 
0.061 
Control 24.3 ± 10.4 24.4 ± 10.5 0.044 0.07 ± 13.0 
Trans fat (g/day) 
mMeD 1.2 ± 0.98 0.6 ± 0.87 0.012 -0.6 ± 0.3 
0.671 
Control 1.3 ± 0.85 1.2 ± 0.60 0.741 -0.1 ± 0.7 
n-6 Fatty acids 
(g/day) 
mMeD 11.3 ± 1.8 12.8 ± 0.8 0.002 1.5 ± 1.7 
0.036 
Control 11.5 ± 2.0 11.6 ± 1.8 0.292 0.1 ± 2.5 
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(g/day) Control 0.18 ± 0.07 0.18 ± 0.06 0.207 -0.00 ± 0.08 
MUFA (g/day) 
mMeD 22.9 ± 2.6 26.0 ± 4.0 0.013 3.1 ± 4.1 
0.019 
Control 25.1 ± 3.7 25.1 ± 3.7 0.091 -0.01 ± 4.6 
PUFA (g/day) 
mMeD 15.2 ± 3.5 17.0 ± 1.5 0.022 1.9 ± 4.1 
0.172 
Control 15.3 ± 3.4 15.3 ± 3.3 0.333 0.00 ± 4.5 
Fiber (g/day) 
mMeD 27.7 ± 8.0 32.0 ± 5.1 0.407 4.2 ± 9.0 
0.431 
Control 29.0 ± 8.0 28.9 ± 8.4 0.431 -0.1 ± 11.1 
minerals 
Iron (mg/day) 
mMeD 29.6 ± 6.5 24.6 ± 3.6 <0.00 -5.0 ± 5.34 
0.029 
Control 28.5 ± 6.0 28.4 ± 6.0 0.139 -0.1 ± 7.8 
Magnesium (mg/day) 
mMeD 253.4 ± 50.5 292.7 ± 36.8 0.348 39.2 ± 58.9 
0.038 
Control 259.0 ± 51.0 257.0 ± 52.2 0.611 -1.9 ± 70.9 
Zinc (mg/day) 
mMeD 9.0 ± 1.1 9.0 ± 0.9 0.650 0.0 ± 1.5 
0.168 
Control 8.9 ± 1.0 8.9 ± 1.1 0.543 -0.05 ± 1.6 
Selenium (μg/day) 
mMeD 118.3 ± 25.2 93.0 ± 13.1 <0.00 -25.3 ± 20.5 
0.004 





mMeD 710.7 ± 895.8 1746.2 ± 973.6 0.006 1035.5 ± 1084.4 
0.032 
Control 856.2 ± 962.3 801.8 ± 924.4 0.214 -54.3 ± 1236.6 
Vitamin E (mg/day) 
mMeD 3.6 ± 0.6 3.8 ± 0.6 0.001 0.2 ± 1.0 
0.650 
Control 3.6 ± 0.6 3.5 ± 0.6 0.226 -0.1 ± 0.8 
Vitamin D (ɥg/day) 
mMeD 1.6 ± 1.2 2.3 ± 1.2 0.319 0.6 ± 1.8 
0.061 
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Vitamin A (RE/day) 
mMeD 1139.9 ± 545.5 1663.2 ± 648.4 0.085 523.3 ± 754.3 
0.152 
Control 1203.8 ± 600.0 1172.1 ± 569.1 0.757 31.6 ± 779.6 
Water-soluble 
vitamins 
Vitamin C (mg/day) 
mMeD 94.4 ± 53.2 141.5 ± 37.3 0.109 47.0 ± 58.7 
0.069 
Control 104.4 ± 54.6 101.9 ± 54.3 0.215 -2.5 ± 71.4 
Vitamin B12 
(ɥg/day) 
mMeD 5.1 ± 2.0 3.7 ± 0.8 0.289 -1.3 ± 2.2 
0.401 
Control 4.6 ± 2.1 4.6 ± 2.1 0.298 0.06 ± 2.8 
Vitamin B6 (mg/day) 
mMeD 1.7 ± 0.3 1.6 ± 0.4 0.581 -0.08 ± 0.5 
0.478 
Control 1.7 ± 0.4 1.7 ± 0.4 0.708 0.00 ± 0.5 
Folic acid (ɥg/day) 
mMeD 334.2 ± 138.8 395.7 ± 102.9 0.828 61.4 ± 170.5 
0.374 
Control 357.6 ± 144.0 355.9 ± 148.0 0.310 -1.6 ± 194.2 
Niacin (mg/day) 
mMeD 29.8 ± 6.3 24.0 ± 3.6 <0.00 -5.7 ± 4.2 
0.018 
Control 28.7 ± 5.5 28.7 ± 5.3 0.326 0.01 ± 7.2 
Riboflavin (mg/day) 
mMeD 2.1 ± 0.4 2.2 ± 0.4 0.006 0.02 ± 0.7 
0.444 
Control 2.1 ± 0.4 2.1 ± 0.4 0.935 0.00 ± 0.6 
Thiamin (mg/day) 
mMeD 2.9 ± 0.5 2.4 ± 0.4 <0.00 -0.5 ± 0.3 
<0.001* 





mMeD 0 0 - 0 
- 
Control 0 0 - 0 
Garlic (g/day) 
mMeD 0.68 ± 1.87 1.24 ± 3.47 <0.00 0.56 ± 1.22 
<0.001* 
Control 0.70 ± 2.00 0.59 ± 1.55 0.803 -0.11 ± 2.52 
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Control 8.0 ± 1.89 7.4 ± 3.22 0.241 -0.6 ± 1.20 
Ginger (g/day) 
mMeD 0.32 ± 0.87 1.0 ± 0.9 0.023 0.7 ± 1.5 
0.015 
Control 0.26 ± 0.80 0.20 ± 0.91 0.441 -0.06 ± 0.51 
Saffron (g/day) 
mMeD 0.02 ± 0.11 0.03 ± 0.27 0.095 0.01 ± 0.47 
0.314 
Control 0.02 ± 0.28 0.02 ± 0.54 0.176 -0.00 ± 0.44 
Turmeric (mg/day) 
mMeD 8.4 ± 6.5 10.7 ± 3.8 0.047 2.3 ± 1.3 
0.041 
Control 7.9 ± 4.4 8.0 ± 4.5 0.341 0.1 ± 1.4 
Green/black tea 
(g/day) 
mMeD 4.5 ± 0.4 5.0 ± 1.1 0.057 0.5 ± 1.7 
0.274 
Control 4.1 ± 0.6 4.1 ± 0.6 0.748 0.00 ± 0.8 
Pepper (g/day) 
mMeD 0.7 ± 1.5 5.3 ± 2.3 <0.00 4.6 ± 3.1 
0.031 
Control 0.8 ± 1.1 0.9 ± 1.8 0.188 0.1 ± 1.1 
Thyme/oregano 
(mg/day) 
mMeD 0.04 ± 0.27 29.8 ± 8.1 <0.00 29.7 ± 9.9 
<0.001* 
Control 0.16 ± 0.44 0.13 ± 0.79 0.552 -0.03 ± 0.20 
Rosemary (mg/day) 
mMeD 0.00 ± 0.05 33.4 ± 6.6 <0.00 33.4 ± 8.2 
<0.001* 





mMeD 74.2 ± 24.2 160.3 ± 69.8 0.046 86.1 ± 12.4 
0.068 
Control 68.9 ± 51.1 77.1 ± 44.4 0.121 8.2 ± 10.7 
Flavones (mg/day) 
mMeD 4.2 ± 1.6 5.5 ± 4.8 0.180 1.3 ± 0.9 
0.059 
Control 3.3 ± 5.1 3.1 ± 2.2 0.470 -0.2 ± 0.5 
Flavonols (mg/day) 
mMeD 30.8 ± 8.4 44.5 ± 10.3 0.065 13.7 ± 4.8 
0.214 
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mMeD 11.6 ± 6.1 17.3 ± 9.9 0.080 5.7 ± 3.3 
0.247 
Control 11.0 ± 2.5 11.0 ± 1.9 0.914 0.00 ± 0.47 
Anthocyanidins 
(mg/day) 
mMeD 10.6 ± 5.5 59.3 ± 11.2 <0.00 48.7 ± 10.0 
<0.001* 





mMeD 4.2 ± 3.1 13.7 ± 0.9 0.044 9.5 ± 1.6 
0.049 





mMeD 0.01 ± 0.2 0.2 ± 0.1 0.074 0.19 ± 0.2 
0.033 
Control 0.00 ± 0.1 0.00 ± 0.1 0.234 0.00 ± 0.1 
Caffeine (g/day) 
mMeD 0.004 ± 0.003 0.003 ± 0.001 <0.00 -0.001 ± 0.000 
0.618 




mMeD 2.38 ± 0.21 -1.87 ± 0.86 <0.00 -4.25 ± 1.54 
<0.001* 
Control 2.21 ± 0.44 2.14 ± 1.01 0.771 -0.07 ± 0.62 
DII, Dietary inflammatory index; mMeD, modified Mediterranean Diet; control, Traditional Iranian Diet; MUFA, monou d fatty acids; PUFA, 
polyunsaturated fatty acids. 
Data has been presented as mean ± SD. 
1
obtained from paired t test; except for protein and Vitamin A, that were analyzed via nonparametric Wilcoxon test. P<0.0 ered as significant. 
2
mean changes between end of trial and baseline values. 
3
obtained from MANCOVA test; adjusted for age, gender, body weight, body mass index, education level, supplement us  history and duration of MS, and 
P<0.05 considered as significant. 
Flavonoid intake was estimated based on “USDA Database for the Flavonoid Content of Selected Foods; Release 3.2”. Ot o &macronutrients were 
calculated with N4 software. 
4
 obtained by dietary intakes only. Negative number indicates an anti-inflammatory score, while positive number reflects a ammatory score. 
5
due to the cultural features of Iranian, the intake of alcohol-contained products was close to zero; thus, we modified the st version of MeD by eliminating any 
alcohol beverages e.g. red wine. 
6
 calculated from USDA Database for the Flavonoid Content of Selected Foods Release 3.3 (March 2018) 
7
 calculated from USDA Database for the Isoflavone Content of Selected Foods Release 2.0 (September 2008) 
8
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Table 4. Comparison of fatigue & disability-related variables in patients with relapsing-remitting multip osis that received 
either modified Mediterranean Diet (mMeD) or Traditional Iranian Diet (control). 
Variables Subscale Group Baseline End of trial P-val 2 P-value3 
MFIS 
Physical 
mMeD 31.2 ± 10.4 28.5 ± 8.8 <0.00 -2.7 ± 0.7 
<0.001* 
Control 32.9 ± 9.2 33.7 ± 10.2 0.124 0.8 ± 0.8 
Cognitive 
mMeD 35.8 ± 11.1 30.2 ± 8.5 <0.01 -5.6 ± 1.8 
0.027 
Control 36.6 ± 9.9 36.1 ± 7.1 0.092 -0.5 ± 0.1 
Psychosoc
ial 
mMeD 5.4 ± 3.1 5.2 ± 2.6 0.244 -0.2 ± 0.2 
0.088 
Control 6.0 ± 2.9 6.1 ± 3.4 0.157 0.1 ± 0.4 
Total 
score 
mMeD 72.4 ± 17.2 63.9 ± 14.2 <0.00 -8.5 ± 2.74 
<0.001* 
Control 69.5 ± 13.2 75.9 ± 15.3 0.771 6.4 ± 1.62 
EDSS 
mMeD 1.7 ± 0.7 1.7 ± 0.6 0.334 -0.02 ± 0.07 
0.065 
Control 2.0 ± 0.9 2.1 ± 0.8 0.112 0.1 ± 0.02 
MFIS, Modified Fatigue Impact Scale; EDSS, Extended Disability Status Scale; mMeD, modified Mediterranea control, Traditional Iranian 
Diet; MUFA, monounsaturated fatty acids; PUFA, polyunsaturated fatty acids. 
Data has been presented as mean ± SD. 
1
obtained from paired t test. P<0.05 considered as significant. 
2
mean changes between end of trial and baseline values. 
3
obtained from MANCOVA test; adjusted for age, gender, body weight, body mass index, education level, supp use, family history and duration 
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Table 5. Predictors and covariates for MFIS total score and EDSS in mMeD group. 
Dependent variables Covariates B 
95% CI 
P val djusted R 
Lower Upper 
MFIS total score 
Age 0.035 -0.006 0.068 0.122
.098 
Gender -0.362 -0.388 -0.340 0.950
body weight 0.045 0.033 0.057 0.069
BMI 0.277 0.127 0.428 0.212
education level 0.022 0.018 0.026 0.199
supplement use 0.860 0.510 1.176 0.320
family history 0.232 0.047 0.417 0.478
 duration of MS 1.007 0.946 1.069 0.321
 DII 1.701 1.329 2.073 0.041
 
EDSS 
Age 0.018 -0.024 0.060 0.625
.157 
Gender 0.112 -0.089 0.313 0.164
body weight 1.022 0.142 1.902 0.311
BMI 0.987 0.975 0.998 0.584
education level -0.221 -0.381 -0.061 0.358
supplement use 0.675 0.504 0.846 0.166
family history 1.328 0.297 2.359 0.254
 duration of MS 2.547 2.113 2.981 0.323
 DII 3.809 2.505 5.114 0.067
B, unstandardized regression coefficient; 95% CI, 95% confidence interval of the unstandardized regress fficient. 
MFIS, modified fatigue impact scale; DII, dietary inflammatory index; EDSS, extended disability status MI, body 
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